Heart failure driven by pathological cardiac remodeling — the progressive thickening and scarring of heart muscle — remains one of the leading causes of cardiovascular mortality, yet the molecular switches governing this process are incompletely understood. Identifying endogenous brakes on this remodeling cascade could open entirely new therapeutic avenues beyond conventional drug targets like ACE inhibitors or beta-blockers.
A new investigation published in Acta Pharmacologica Sinica characterizes circKLHL20_009, a human circular RNA, as a protective regulator in pathological cardiac hypertrophy and fibrosis. The study demonstrates that this circRNA functions as a molecular sponge for microRNA miR-31-5p — binding and sequestering it to prevent downstream suppression of target genes. By neutralizing miR-31-5p activity, circKLHL20_009 effectively dampens the β-catenin signaling pathway, a canonical Wnt cascade repeatedly implicated in maladaptive cardiac growth and extracellular matrix deposition. Experimental models showed that increasing circKLHL20_009 expression attenuated hypertrophic markers and reduced fibrotic remodeling, while its depletion worsened these outcomes.
Circular RNAs have emerged over the past decade as a compelling class of non-coding RNA regulators with unusual stability — their covalently closed loop structure resists the exonucleases that rapidly degrade linear RNA. This biochemical durability makes them attractive as both biomarkers and potential therapeutic targets. The circRNA-miRNA sponge axis is now a well-established regulatory mechanism, but most prior cardiac circRNA studies focused on rodent-specific sequences; the human origin of circKLHL20_009 is a meaningful translational advantage. That said, the work appears to rely primarily on cell-based and animal models, and the leap to human cardiac physiology remains unproven. β-catenin pathway modulation also carries inherent complexity given its roles in cell proliferation and cancer biology, meaning therapeutic amplification of this circRNA would require careful off-target profiling. Overall, this is a mechanistically detailed but incremental advance — adding a named molecular actor to a well-mapped signaling landscape rather than reshaping it.